Compare AANJANEYA LIFECARE with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS GLENMARK PHARMA DR. DATSONS LABS/
GLENMARK PHARMA
 
P/E (TTM) x -10.9 11.9 - View Chart
P/BV x 0.2 1.7 9.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
GLENMARK PHARMA
Mar-19
DR. DATSONS LABS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs126712 17.7%   
Low Rs31484 6.4%   
Sales per share (Unadj.) Rs133.0349.6 38.0%  
Earnings per share (Unadj.) Rs0.232.8 0.5%  
Cash flow per share (Unadj.) Rs6.644.3 14.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs128.8198.6 64.8%  
Shares outstanding (eoy) m31.66282.17 11.2%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.61.7 34.4%   
Avg P/E ratio x516.118.2 2,831.2%  
P/CF ratio (eoy) x11.813.5 87.8%  
Price / Book Value ratio x0.63.0 20.2%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m2,477168,625 1.5%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m5620,561 0.3%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m4,21198,655 4.3%  
Other income Rs m792,081 3.8%   
Total revenues Rs m4,289100,736 4.3%   
Gross profit Rs m56915,858 3.6%  
Depreciation Rs m2043,259 6.3%   
Interest Rs m4303,346 12.9%   
Profit before tax Rs m1311,335 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m63,756 0.2%   
Profit after tax Rs m59,250 0.1%  
Gross profit margin %13.516.1 84.0%  
Effective tax rate %48.033.1 144.9%   
Net profit margin %0.19.4 1.2%  
BALANCE SHEET DATA
Current assets Rs m6,85266,968 10.2%   
Current liabilities Rs m6,71140,211 16.7%   
Net working cap to sales %3.327.1 12.3%  
Current ratio x1.01.7 61.3%  
Inventory Days Days16183 193.0%  
Debtors Days Days31881 392.2%  
Net fixed assets Rs m3,67333,322 11.0%   
Share capital Rs m317282 112.2%   
"Free" reserves Rs m3,76155,770 6.7%   
Net worth Rs m4,07856,052 7.3%   
Long term debt Rs m1,67135,738 4.7%   
Total assets Rs m12,633132,888 9.5%  
Interest coverage x1.04.4 23.5%   
Debt to equity ratio x0.40.6 64.3%  
Sales to assets ratio x0.30.7 44.9%   
Return on assets %3.49.5 36.3%  
Return on equity %0.116.5 0.7%  
Return on capital %7.717.8 43.1%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96462,998 1.5%   
Fx outflow Rs m60722,859 2.7%   
Net fx Rs m35740,140 0.9%   
CASH FLOW
From Operations Rs m1,34513,242 10.2%  
From Investments Rs m-2,256-6,990 32.3%  
From Financial Activity Rs m-1,200-7,387 16.2%  
Net Cashflow Rs m-2,111-2,971 71.0%  

Share Holding

Indian Promoters % 4.5 48.3 9.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 1.4 34.4 3.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.5 896.2%  
Shareholders   20,807 56,727 36.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS